226 related articles for article (PubMed ID: 26985856)
1. SKA1 regulates the metastasis and cisplatin resistance of non-small cell lung cancer.
Shen L; Yang M; Lin Q; Zhang Z; Miao C; Zhu B
Oncol Rep; 2016 May; 35(5):2561-8. PubMed ID: 26985856
[TBL] [Abstract][Full Text] [Related]
2. SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway.
Chen K; Abuduwufuer A; Zhang H; Luo L; Suotesiyali M; Zou Y
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6935-6943. PubMed ID: 31486493
[TBL] [Abstract][Full Text] [Related]
3. Effect of vitamin D on malignant behavior of non-small cell lung cancer cells.
Songyang Y; Song T; Shi Z; Li W; Yang S; Li D
Gene; 2021 Feb; 768():145309. PubMed ID: 33197518
[TBL] [Abstract][Full Text] [Related]
4. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
[TBL] [Abstract][Full Text] [Related]
5. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
Gao J; Meng Q; Zhao Y; Chen X; Cai L
BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
[TBL] [Abstract][Full Text] [Related]
6. MiR-204 reduces cisplatin resistance in non-small cell lung cancer through suppression of the caveolin-1/AKT/Bad pathway.
Huang G; Lou T; Pan J; Ye Z; Yin Z; Li L; Cheng W; Cao Z
Aging (Albany NY); 2019 Apr; 11(7):2138-2150. PubMed ID: 30981205
[TBL] [Abstract][Full Text] [Related]
7. Up-regulated HMGB1 in the pleural effusion of non-small cell lung cancer (NSCLC) patients reduces the chemosensitivity of NSCLC cells.
Ma Y; Kang S; Wu X; Han B; Jin Z; Guo Z
Tumori; 2018 Oct; 104(5):338-343. PubMed ID: 28885675
[TBL] [Abstract][Full Text] [Related]
8. TAZ inhibition restores sensitivity of cisplatin via AKT/mTOR signaling in lung adenocarcinoma.
Xu W; Wei Y; Li Y; Yin Y; Yuan W; Yang Y; Zhao W; Wu J
Oncol Rep; 2017 Sep; 38(3):1815-1821. PubMed ID: 28737828
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest.
Sarin N; Engel F; Kalayda GV; Mannewitz M; Cinatl J; Rothweiler F; Michaelis M; Saafan H; Ritter CA; Jaehde U; Frötschl R
PLoS One; 2017; 12(7):e0181081. PubMed ID: 28746345
[TBL] [Abstract][Full Text] [Related]
10. FOXC2 promotes epithelial-mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells.
He Y; Xie H; Yu P; Jiang S; Wei L
Cancer Chemother Pharmacol; 2018 Dec; 82(6):1049-1059. PubMed ID: 30302523
[TBL] [Abstract][Full Text] [Related]
11. IL-6 signaling contributes to cisplatin resistance in non-small cell lung cancer via the up-regulation of anti-apoptotic and DNA repair associated molecules.
Duan S; Tsai Y; Keng P; Chen Y; Lee SO; Chen Y
Oncotarget; 2015 Sep; 6(29):27651-60. PubMed ID: 26313152
[TBL] [Abstract][Full Text] [Related]
12. CHD1L contributes to cisplatin resistance by upregulating the ABCB1-NF-κB axis in human non-small-cell lung cancer.
Li Y; He LR; Gao Y; Zhou NN; Liu Y; Zhou XK; Liu JF; Guan XY; Ma NF; Xie D
Cell Death Dis; 2019 Feb; 10(2):99. PubMed ID: 30718500
[TBL] [Abstract][Full Text] [Related]
13. Silence of fibronectin 1 increases cisplatin sensitivity of non-small cell lung cancer cell line.
Gao W; Liu Y; Qin R; Liu D; Feng Q
Biochem Biophys Res Commun; 2016 Jul; 476(1):35-41. PubMed ID: 27207836
[TBL] [Abstract][Full Text] [Related]
14. Activation of ERK1/2 and Akt is associated with cisplatin resistance in human lung cancer cells.
Wang M; Liu ZM; Li XC; Yao YT; Yin ZX
J Chemother; 2013 Jun; 25(3):162-9. PubMed ID: 23783141
[TBL] [Abstract][Full Text] [Related]
15. MDMX is a prognostic factor for non-small cell lung cancer and regulates its sensitivity to cisplatin.
Zhao H; Xie YZ; Xing R; Sun M; Chi F; Zeng YC
Cell Oncol (Dordr); 2017 Aug; 40(4):357-365. PubMed ID: 28567715
[TBL] [Abstract][Full Text] [Related]
16. Deoxyshikonin inhibits cisplatin resistance of non-small-cell lung cancer cells by repressing Akt-mediated ABCB1 expression and function.
Zhang S; Wang Y
J Biochem Mol Toxicol; 2020 Oct; 34(10):e22560. PubMed ID: 32627280
[TBL] [Abstract][Full Text] [Related]
17. Musashi1 Promotes Non-Small Cell Lung Carcinoma Malignancy and Chemoresistance via Activating the Akt Signaling Pathway.
Lang Y; Kong X; He C; Wang F; Liu B; Zhang S; Ning J; Zhu K; Xu S
Cell Physiol Biochem; 2017; 44(2):455-466. PubMed ID: 29141252
[TBL] [Abstract][Full Text] [Related]
18. Allicin Overcomes Hypoxia Mediated Cisplatin Resistance in Lung Cancer Cells through ROS Mediated Cell Death Pathway and by Suppressing Hypoxia Inducible Factors.
Pandey N; Tyagi G; Kaur P; Pradhan S; Rajam MV; Srivastava T
Cell Physiol Biochem; 2020 Aug; 54(4):748-766. PubMed ID: 32809300
[TBL] [Abstract][Full Text] [Related]
19. Akt1 inhibition by RNA interference sensitizes human non-small cell lung cancer cells to cisplatin.
Lee MW; Kim DS; Min NY; Kim HT
Int J Cancer; 2008 May; 122(10):2380-4. PubMed ID: 18224693
[TBL] [Abstract][Full Text] [Related]
20. Phloretin exhibits an anticancer effect and enhances the anticancer ability of cisplatin on non-small cell lung cancer cell lines by regulating expression of apoptotic pathways and matrix metalloproteinases.
Ma L; Wang R; Nan Y; Li W; Wang Q; Jin F
Int J Oncol; 2016 Feb; 48(2):843-53. PubMed ID: 26692364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
